Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Levisoprenaline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 7/20 | 1.00 |
| ▸ | ADRB1 known ✓ | P08588 | 5/20 | 1.00 |
| ▸ | ADRB3 known ✓ | P13945 | 5/20 | 0.97 |
| ▸ | MAPT | P10636 | 7/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 6/20 | 1.00 |
| ▸ | TSHR | P16473 | 4/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 4/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 1.00 |
| ▸ | BLM | P54132 | 4/20 | 1.00 |
| ▸ | POLB | P06746 | 3/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 3/20 | 1.00 |
| ▸ | GAA | P10253 | 2/20 | 1.00 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 4/20 | 0.97 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.97 |
| ▸ | MTOR | P42345 | 3/20 | 0.97 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.97 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.97 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Isoproterenol SCHEMBL9614622 | 1.00 | MAPT (1.00) | MAPTADRB2KDM4ETDP1ADRB1 | |
| Isoproterenol SCHEMBL28872988 | 1.00 | MAPT (1.00) | MAPTADRB2KDM4ETDP1ADRB1 | |
| Isoproterenol SCHEMBL3672791 | 1.00 | MAPT (1.00) | MAPTADRB2KDM4ETDP1ADRB1 | |
| Isoproterenol SCHEMBL7627 | 1.00 | MAPT (1.00) | MAPTADRB2KDM4ETDP1ADRB1 | |
| Isoproterenol SCHEMBL4166 | 0.98 | MAPT (1.00) | MAPTADRB2KDM4ETDP1ADRB1 | |
| Isoproterenol SCHEMBL3253794 | 0.98 | MAPT (1.00) | MAPTADRB2KDM4ETDP1ADRB1 | |
| Isoproterenol SCHEMBL29386243 | 0.98 | MAPT (1.00) | MAPTADRB2KDM4ETDP1ADRB1 | |
| Isoproterenol SCHEMBL4165 | 0.98 | MAPT (1.00) | MAPTADRB2KDM4ETDP1ADRB1 | |
| Levisoprenaline SCHEMBL250806 | 0.98 | MAPT (1.00) | MAPTADRB2KDM4ETDP1ADRB1 | |
| Isoproterenol SCHEMBL29519146 | 0.98 | MAPT (1.00) | MAPTADRB2KDM4ETDP1ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250276107-A1 | HYDROGEL SYSTEMS AND METHODS FOR TREATING FISTULA AND OTHER INDICATIONS | TERASAKI INSTITUTE FOR BIOMEDICAL INNOVATION (US) | 2025-09-04 | — | — | US | claimed |
| US-20260007705-A1 | PROBIOTIC COMPOSITIONS FOR PRODUCTION OF DOPAMINE | UNIV IOWA STATE RES FOUND INC (US) | 2026-01-08 | — | — | US | disclosed |
| EP-4635987-A2 | NOVEL ANTIGEN-BINDING CHIMERIC PROTEINS AND METHODS AND USES THEREOF | VIB VZW (BE) | 2025-10-22 | — | — | EP | disclosed |
| US-12440519-B2 | Probiotic compositions for production of dopamine | LOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2025-10-14 | — | — | US | disclosed |
| EP-3897556-B1 | COSMETIC USE OF A SHORT CHAIN FATTY ACID (SCFA) FOR PREVENTING AND/OR TREATING DRY SKIN AND/OR AGED SKIN | OREAL (FR) | 2025-09-24 | — | — | EP | disclosed |
| US-20250276107-A1 | HYDROGEL SYSTEMS AND METHODS FOR TREATING FISTULA AND OTHER INDICATIONS | TERASAKI INSTITUTE FOR BIOMEDICAL INNOVATION (US) | 2025-09-04 | — | — | US | disclosed |
| EP-3704160-B1 | NOVEL ANTIGEN-BINDING CHIMERIC PROTEINS AND METHODS AND USES THEREOF | VIB VZW (BE) | 2025-08-20 | — | — | EP | disclosed |
| US-20240174767-A1 | Novel Antigen-Binding Chimeric Proteins and Methods and Uses Thereof | VRIJE UNIVERSITEIT BRUSSEL (BE) | 2024-05-30 | — | — | US | disclosed |
| US-11873347-B2 | Antigen-binding chimeric proteins and methods and uses thereof | VIB VZW (BE) | 2024-01-16 | — | — | US | disclosed |
| US-20220313751-A1 | PROBIOTIC COMPOSITIONS FOR PRODUCTION OF DOPAMINE | IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC. | 2022-10-06 | — | — | US | disclosed |
| US-11357803-B2 | Probiotic compositions for production of dopamine | IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2022-06-14 | — | — | US | disclosed |
| US-20140024677-A1 | METHODS FOR INDUCING MITOCHONDRIAL BIOGENESIS | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2014-01-23 | — | — | US | disclosed |
| WO-2008121717-A1 | ELECTROPHYSIOLOGICAL METHOD TO PHARMACOLOGICALLY CLASSIFY LIGANDS FOR GS PROTEIN-COUPLED RECEPTORS | GEISINGER VENTURES | 2008-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260007705-A1 | PROBIOTIC COMPOSITIONS FOR PRODUCTION OF DOPAMINE | PRLHR, SLC6A2, TPH2 | ADRB2 99/4885ADRB1 140/4885ADRB3 191/4885 |
| US-20140024677-A1 | METHODS FOR INDUCING MITOCHONDRIAL BIOGENESIS | TFAM, TXNRD2, CPT1B | ADRB2 195/4885ADRB1 179/4885ADRB3 200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.